P3354
P3781
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PatientsRucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial CancerPARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 MutationsA Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerMesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant MesotheliomaA Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following ChemotherapyBevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or EndometriumRucaparib in Nonmetastatic prOstAte With BRCAnessRucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum TherapyRucaparib Hepatic Impairment Study in Patients With a Solid TumorA Study of Rucaparib in Japanese Patients With a Previously-treated Solid TumorTrial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene MutationsDocetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair DeficiencyRucaparib and Irinotecan in Cancers With Mutations in DNA RepairRucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung CancerA Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyWindow of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast TumorsRucaparib Maintenance Therapy in Advanced Cervical CancerDrug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral ContraceptivesA Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast CancerCombination Rucaparib With Nivolumab in Small Cell Lung CarcinomaA Phase II Study Of Nivolumab/ Bevacizumab/RucaparibA Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene DeficiencyRucaparib and Nivolumab in Patients With Prostate or Endometrial CancerRucaparib in Patients With Locally Advanced or Metastatic Urothelial CarcinomaA Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA MutationA Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic RegimensRucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian CancerAn Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate CancerLiposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary CancerA Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal CancerTrial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer.A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic SignatureA Phase 2 Study Exploring The Safety And Efficacy Of Novel Drug Treatment In Subjects With Diabetic Macular Edema (DME)Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesPlanning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialRucaparib, Ramucirumab and Nivolumab in Patients Who Have Had Treatment for Gastric and Esophageal Adenocarcinoma
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Rucaparib
@de
Rucaparib
@es
Rucaparib
@fr
Rucaparib
@vi
Rukaparib
@sh
Rukaparib
@sr
rucaparib
@en
type
label
Rucaparib
@de
Rucaparib
@es
Rucaparib
@fr
Rucaparib
@vi
Rukaparib
@sh
Rukaparib
@sr
rucaparib
@en
altLabel
AG-014699
@en
AG014699
@en
AG14447
@en
PF-01367338
@en
Rubraca
@en
Rucaparib
@en
prefLabel
Rucaparib
@de
Rucaparib
@es
Rucaparib
@fr
Rucaparib
@vi
Rukaparib
@sh
Rukaparib
@sr
rucaparib
@en